BioCentury | Apr 1, 2013
Clinical News

OHR/AVR118: Phase II data

...not be reached for next steps. In 2009, the company acquired OHR/AVR118 from the now-defunct Advanced Viral Research Corp....
BioCentury | Dec 14, 2009
Clinical News

OHR118: Phase II data

...Society of Cachexia and Wasting Disorders meeting in Barcelona. Ohr acquired OHR118 from the now-defunct Advanced Viral Research Corp....
BioCentury | Dec 7, 2009
Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

...pipeline, which includes compounds from Advanced Viral and Genaera Corp. Ohr acquired AVR118 and AVR123 from Advanced Viral...
...a topical formulation of OHR118 in Phase I testing for wound healing, was renamed OHR123. Advanced Viral...
...and diabetes. Genaera's board voted to dissolve the biotech in June (see BioCentury, June 22). Advanced Viral Research Corp....
BioCentury | Feb 2, 2009
Company News

Advanced Viral cancer, infectious news

...to Y.A. Global Investments L.P., to whom it owes $2.2 million in principal and interest. Advanced Viral's...
...30, 2008, Advanced Viral had $232,769 in cash and a nine-month operating loss of $2.2 million. Advanced Viral Research Corp....
BioCentury | Mar 3, 2008
Company News

Advanced Viral, Northeastern University deal

...screening technology. The company will have rights to resulting IP. Financial terms were not disclosed. Advanced Viral Research Corp....
BioCentury | Feb 4, 2008
Product Development

Proteasome inhibitors on deck

...Solid tumors, lymphomas Ph I Nereus NPI-0052 MM, solid tumors, leukemia and lymphoma Ph I Advanced Viral...
BioCentury | Dec 10, 2007
Company News

Advanced Viral deal

...Hughes will join ADVR as CSO and VP of research, respectively. Cetek no longer exists. Advanced Viral Research Corp....
BioCentury | Dec 10, 2007
Company News

Advanced Viral management update

Advanced Viral Research Corp. (ADVR), Yonkers, N.Y. Business: Cancer, Infectious Hired: Vincent Gullo as CSO, formerly VP of drug discovery at Cetek Corp. ; and Dallas Hughes as VP of research, formerly SVP of technology...
BioCentury | Oct 8, 2007
Clinical News

AVR118: Phase II started

...from this first cohort, up to 30 additional patients could be enrolled in the trial. Advanced Viral Research Corp....
BioCentury | Sep 10, 2007
Clinical News

AVR118: Phase II start

...Pending the results from this first cohort, the trial could enroll at least 32 patients. Advanced Viral Research Corp....
Items per page:
1 - 10 of 86
BioCentury | Apr 1, 2013
Clinical News

OHR/AVR118: Phase II data

...not be reached for next steps. In 2009, the company acquired OHR/AVR118 from the now-defunct Advanced Viral Research Corp....
BioCentury | Dec 14, 2009
Clinical News

OHR118: Phase II data

...Society of Cachexia and Wasting Disorders meeting in Barcelona. Ohr acquired OHR118 from the now-defunct Advanced Viral Research Corp....
BioCentury | Dec 7, 2009
Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

...pipeline, which includes compounds from Advanced Viral and Genaera Corp. Ohr acquired AVR118 and AVR123 from Advanced Viral...
...a topical formulation of OHR118 in Phase I testing for wound healing, was renamed OHR123. Advanced Viral...
...and diabetes. Genaera's board voted to dissolve the biotech in June (see BioCentury, June 22). Advanced Viral Research Corp....
BioCentury | Feb 2, 2009
Company News

Advanced Viral cancer, infectious news

...to Y.A. Global Investments L.P., to whom it owes $2.2 million in principal and interest. Advanced Viral's...
...30, 2008, Advanced Viral had $232,769 in cash and a nine-month operating loss of $2.2 million. Advanced Viral Research Corp....
BioCentury | Mar 3, 2008
Company News

Advanced Viral, Northeastern University deal

...screening technology. The company will have rights to resulting IP. Financial terms were not disclosed. Advanced Viral Research Corp....
BioCentury | Feb 4, 2008
Product Development

Proteasome inhibitors on deck

...Solid tumors, lymphomas Ph I Nereus NPI-0052 MM, solid tumors, leukemia and lymphoma Ph I Advanced Viral...
BioCentury | Dec 10, 2007
Company News

Advanced Viral deal

...Hughes will join ADVR as CSO and VP of research, respectively. Cetek no longer exists. Advanced Viral Research Corp....
BioCentury | Dec 10, 2007
Company News

Advanced Viral management update

Advanced Viral Research Corp. (ADVR), Yonkers, N.Y. Business: Cancer, Infectious Hired: Vincent Gullo as CSO, formerly VP of drug discovery at Cetek Corp. ; and Dallas Hughes as VP of research, formerly SVP of technology...
BioCentury | Oct 8, 2007
Clinical News

AVR118: Phase II started

...from this first cohort, up to 30 additional patients could be enrolled in the trial. Advanced Viral Research Corp....
BioCentury | Sep 10, 2007
Clinical News

AVR118: Phase II start

...Pending the results from this first cohort, the trial could enroll at least 32 patients. Advanced Viral Research Corp....
Items per page:
1 - 10 of 86